Levothyrok. Merck sued by 42 patients in Toulouse



[ad_1]

Forty-two Levothyrox plaintiffs sued the Merck laboratory in the Toulouse tribunal de grande instance, demanding compensation, appraisals and the maintenance of the marketing of the old formula, it was learned on Tuesday 10

This summons, filed on July 6, is a fixed-day badignment, which means that the case will be considered on the merits, but on an expedited basis. The presidency of the court accepted this referral in urgency and fixed the hearing on July 19 at 14H, said the plaintiffs' lawyer, Jacques Lévy.

Insomnia, headaches …

The Levothyrox, Prescription against hypothyroidism, changed formula in France in March 2017. From July and August, thousands of patients began to report side effects sometimes very annoying (fatigue, headache, insomnia, dizziness, joint pain and muscle and hair loss). "For several months the applicants have suffered serious disturbances in the total ignorance of the causes of the latter" it is therefore "manifest that all the victims are entitled to obtain compensation for the damage suffered, in the first place, an injury of anxiety " can be read in the subpoena obtained by AFP

Moreover, " by not informing patients of the risks posed by the new Levothyrox, it is undeniable that the latter suffered moral injury which must be repaired ". Thus, the plaintiffs claim the payment of 15,000 euros to each of the plaintiffs in respect of the injury of anxiety and 15,000 euros in respect of non-pecuniary damage.

Remove sales the current version

In addition, they claim the maintenance of the marketing of the old formula and ask the court to order an expertise in order to determine the bodily injury suffered by the plaintiffs. In June, the court of appeal of Toulouse confirmed the sentence pronounced in November which ordered the laboratories Merck to deliver "without delay" the old formula of the drug to 25 patients of Haute-Garonne

The third pharmacovigilance report on Levothyrox, released Friday by the Agence du médicament, still does not explain the wave of adverse effects attributed by some patients to the new formula of this drug for thyroid.

[ad_2]
Source link